Upon initiation of a patent infringement action between branded and generic pharmaceutical companies, the Hatch-Waxman Act (21 U.S.C. ยง 355(j)) provides for an automatic 30-month stay of Food and Drug Administration approval...more
3/28/2016
/ Abbott Laboratories ,
Abbreviated New Drug Application (ANDA) ,
America Invents Act ,
Automatic Stay ,
Discovery ,
Eli Lilly ,
FDA Approval ,
Generic Drugs ,
Hatch-Waxman ,
Inter Partes Review (IPR) Proceeding ,
Novartis ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Tolling